• Product Name: Meningococcal Polysaccharide (Serogroups A, C, Y and W-135) Diphtheria Toxoid Conjugate Vaccine
• Tradename: Menactra
• Manufacturer: Sanofi Pasteur Inc.
• Vaccine Ontology ID: VO_0000071
• CDC CVX code: 114
• Type: Conjugate vaccine
• Status: Licensed
• Location Licensed: USA (License #1725), Canada
• Host Species for Licensed Use: Human
• Allergen: Latex
• Preparation: Cultured on Mueller Hinton agar and grown in Watson Scherp media. The polysaccharides are extracted from the N meningitidis cells and purified by centrifugation, detergent precipitation, alcohol precipitation, solvent extraction and diafiltration (FDA: Menactra).
• Immunization Route: Intramuscular injection (i.m.)
• Storage: Store at 2° to 8°C (35° to 46°F). DO NOT FREEZE.
• Approved Age for Licensed Use: 2-55 years of age.
• Contraindication: This vaccine should not be administered to anyone with known hypersensitivity to any component of Menactra vaccine including diphtheria toxoid, or a life-threatening reaction after previous administration of a vaccine containing similar components (FDA: Menactra).
• Description: Contains Neisseria meningitidis serogroup A, C, Y and W-135 capsular polysaccharide antigens individually conjugated to diphtheria toxoid protein. Menactra vaccine is not indicated for immunization against diphtheria (FDA: Menactra).

• Product Name: Meningococcal Polysaccharide Vaccine, Groups A, C, Y, W135 Combined
• Tradename: Menomune-A/C/Y/W-135
• Manufacturer: Sanofi Pasteur, Inc.
• Vaccine Ontology ID: VO_0000072
• CDC CVX code: 32
• Type: Live, attenuated vaccine
• Status: Licensed
• Location Licensed: USA (License #1725)
• Host Species for Licensed Use: Human
• Antigen: Meningococcal Polysaccharide Vaccine, Groups A, C, Y and W-135 Combined
• Preparation: MEMOMUNE is cultivated with Mueller Hinton agar and Watson Scherp media and is freeze-dried with the group-specific polysaccharide antigens from Neisseria meningitidis, Group A, Group C, Group Y and Group W-135 (FDA: Menomune– A/C/Y/W-135).
• Immunization Route: subcutaneous injection
• Storage: Store the freeze-dried vaccine and reconstituted vaccine, when not in use, at 2° to 8°C (35° to 46°F).
• Approved Age for Licensed Use: 2 years of age and older
• Contraindication: Individuals with known sensitivity to thimerosal or any other component of the vaccine.
• Description: Meningococcal Polysaccharide Vaccine, Groups A, C, Y and W-135 Combined, is indicated for active immunization against invasive meningococcal disease caused by these serogroups (FDA: Menomune– A/C/Y/W-135).

Human Response

• Immune Response: Clinical studies reported antibodies were seen in 90-100% of those who were vaccinated with Menactra (FDA: Menactra).
• Side Effects: Side effects of vaccination include: injection site reactions, headache, fatigue, irritability and fever.

Human Response

• Immune Response: Measurable levels of antibodies against the group A and C polysaccharides decrease markedly during the first 3 years following a single dose of vaccine (FDA: Menomune– A/C/Y/W-135).
• Side Effects: Side effects of vaccination include: pain and redness of injection site, fever and/or headache (FDA: Menomune– A/C/Y/W-135).
• Efficacy: The serogroup A polysaccharide induces and antibody response in children as young as 3 months of age, the serogroup C component can be poorly immunogenic in recipients who are less than 18 to 24 months of age 5. The serogroups A and C have demonstrated estimated clinical efficacies of 85% to 100% in older children and adults. Serogroups Y and W-135 polysaccharides are safe and immunogenic in adults and in children greater than 2 years of age (FDA: Menomune– A/C/Y/W-135).